Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth
| Autor: | Iliana Garcia-Ortega, Thomas J. Raedler, Tamara Pringsheim, Sabina Abidi, Kevin Jackson, Tania Lecomte, Irfan Mian, Kim Jackson, D. Addington |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Canada Adolescent business.industry Early onset schizophrenia Cognition Canadian Schizophrenia Guidelines 030227 psychiatry Pharmacological treatment 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine Pharmacotherapy Psychotic Disorders Practice Guidelines as Topic Schizophrenia Medicine Humans business Psychiatry Child 030217 neurology & neurosurgery Clinical psychology Schizophrenia spectrum |
| Zdroj: | Canadian journal of psychiatry. Revue canadienne de psychiatrie. 62(9) |
| ISSN: | 1497-0015 |
| Popis: | Objective: Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Methods: A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts. Results: Recommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain. Conclusions: Canadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|